These innovative agents represent a significant advancement in the therapy of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in controlling blood glucose levels. Trizepatide, on the other hand, targets all three incretin receptors – GLP-1, GIP, and glucose – leading to a additive effect.